ArticleScience (New York, N.Y.)2016
Prostaglandin E₂ constrains systemic inflammation through an innate lymphoid cell-IL-22 axis.
Article in Science (New York, N.Y.), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 108 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
108 citing papers in PubMed, 182 citations in OpenAlex.
- AA in Rheumatoid Arthritis and Lupus.Reviews of physiology, biochemistry and pharmacology · 2027Review
- Gut microbiota in chronic inflammation: the interplay with lipid mediators.Gut microbes · 2026Review
- The update of prostaglandin E2 receptor subtype 4 (EP4) in inflammatory diseases.Genes & diseases · 2026Review
- ILC3s as central regulators of mucosal homeostasis and disease pathogenesis (Review).International journal of molecular medicine · 2026Review
- PGE2 Enhances Human ILC3 Function but Constrains ILC2-to-ILC3 Plasticity.European journal of immunology · 2026Article
- Integrated multi-omics reveals Enterococcus faecalis JM263 alleviates high-concentrate diet-induced hepatic injury via the gut-liver axis in goats.Microbiome · 2026Article
- Oxidative stress affects intestinal health by inhibiting the differentiation of porcine intestinal epithelial cells through producing arachidonic acid.Science China. Life sciences · 2026Article
- 12R-HETE acts as an endogenous ligand for Nur77 in the intestines and regulates NKp46Science advances · 2026Article
- Neoadjuvant sintilimab, albumin-bound paclitaxel, and carboplatin for locally advanced, resectable esophageal squamous cell carcinoma: clinical study and mechanistic exploration.NPJ precision oncology · 2026Article
- Experimental Research Progress of mPGES-1 Inhibitor 2,5- dimethylcelecoxib in Various Diseases.Current medicinal chemistry · 2026Review
- Lung Tissue Metabolome Investigation Reveals the In Vivo Effects of Zhuye Shigao Decoction in an LPS-Induced Acute Pneumonia Model in Mice.Mediators of inflammation · 2026Article
- Eosinophil-derived COX-2 protects against experimental colitis through the PGEbioRxiv : the preprint server for biology · 2025Article
- Sustained-Release Intra-Articular Drug Delivery: PLGA Systems in Clinical Context and Evolving Strategies.Pharmaceutics · 2025Review
- A CD4Immunity · 2025Article
- Enteric tuft cell inflammasome activation drives NKp46+ILC3 IL22 via PGD2 and inhibits Salmonella.The Journal of experimental medicine · 2025Article
- Severe anemia in preterm infants associated with increased bacterial virulence potential and metabolic disequilibrium.Pediatric research · 2025Article
- Enteric GABAergic neuron-derived γ-aminobutyric acid initiates expression of Igfbp7 to sustain ILC3 homeostasis.Nature immunology · 2025Article
- Mass spectrometry imaging reveals spatial metabolic variation and the crucial role of uridine metabolism in liver injury caused by Schistosoma japonicum.PLoS neglected tropical diseases · 2025Article
- The evolution of cancer immunotherapy: a comprehensive review of its history and current perspectives.Korean journal of clinical oncology · 2024Review
- Exploring the underlying pharmacological, immunomodulatory, and anti-inflammatory mechanisms of phytochemicals against wounds: a molecular insight.Inflammopharmacology · 2024Review
48 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors at 7 institutions in 4 countries.
Funding
Abstract
Systemic inflammation, which results from the massive release of proinflammatory molecules into the circulatory system, is a major risk factor for severe illness, but the precise mechanisms underlying its control are not fully understood. We observed that prostaglandin E2 (PGE2), through its receptor EP4, is down-regulated in human systemic inflammatory disease. Mice with reduced PGE2 synthesis develop systemic inflammation, associated with translocation of gut bacteria, which can be prevented by treatment with EP4 agonists. Mechanistically, we demonstrate that PGE2-EP4 signaling acts directly on type 3 innate lymphoid cells (ILCs), promoting their homeostasis and driving them to produce interleukin-22 (IL-22). Disruption of the ILC-IL-22 axis impairs PGE2-mediated inhibition of systemic inflammation. Hence, the ILC-IL-22 axis is essential in protecting against gut barrier dysfunction, enabling PGE2-EP4 signaling to impede systemic inflammation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.